This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...

However, the stock market largely attributes value to a company based on its ability to generate earnings in the future. Based on Lilly’s next twelve months forward P/E ratio, investors are paying ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...